2013-03-11 14:20:23 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to ImmunoGen, Inc. and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering ImmunoGen, Inc. (IMGN). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential ImmunoGen, Inc. investor.
Report Summary: ImmunoGen, Inc. is a low quality company with a neutral outlook. ImmunoGen, Inc. has weak business growth and is run by inefficient management. The trend in ImmunoGen, Inc. fair value exchange rate against its closest rated-competitor, Ironwood Pharmaceuticals, Inc., has been depreciating over the past 2 weeks. When compared to its closest competitor, ImmunoGen, Inc. shows less overvaluation and is equally likely to underperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management and price,
performing an in-depth analysis of ImmunoGen, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.